BioPharmX presented results of two studies comparing oral and topical minocycline gel during a poster session at the Skin Disease Education Foundation’s 17th annual Las Vegas Dermatology Seminar.
Study findings that a family history of acne and various lifestyle factors were associated with adult acne in women was among recent developments in acne reported on Healio.com/Dermatology. Other recent developments included research finding a combination of a superficial chemical peel, subcision and fractional CO2 laser resurfacing after tumescent anesthesia is a safe and effective treatment for rolling acne scars.
BioPharmX announced it has begun enrollment of patients in its phase 2b clinical trial measuring the efficacy and safety of BPX-10 for treating acne vulgaris. The OPAL study is a 12-week multi-center, double-blind vehicle-controlled study of BPX-01, a fully solubilized topical minocycline gel that delivers the drug directly to the acne source while avoiding systemic exposure.
Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes
Acne vulgaris is a multifactorial skin disease associated with the colonization of Propionibacterium acnes. Antibiotics are a mainstay of treatment for acne, yet the emergence of resistance against the currently approved antibiotics is a serious concern. In this case report, a slow responder had multiple Propionibacterium acnes isolates with varied levels of sensitivity to the conventional antibiotics.
Spinal Schwannoma and Meningioma Mimicking a Single Mass at the Craniocervical Junction Subsequent to Remote Radiation Therapy for Acne Vulgaris
Schwannomas and meningiomas are relatively common tumors of the nervous system. They have been reported in the literature as existing concurrently as a single mass, but very rarely have been shown to present at the craniocervical junction.
Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results
Acne vulgaris (AV) is a chronic inflammatory skin disease that affects 80% to 90% of persons by the age of 21.1 Oral antibiotics, such as tetracycline, doxycycline, and minocycline, have been a mainstay of treatment for moderate-to-severe AV; however, their systemic side effects warrant the need for alternative treatments.
June is Acne Awareness Month. Recent developments reported on Healio.com/Dermatology include research finding that Epiduo Forte Gel displayed significantly greater efficacy when compared with vehicle in treating patients with moderate-to-severe acne, and that a new regimen, called CoMMPlete, effectively reduced acne among a cohort of student athletes.
How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy
After cessation of successful initial acne therapy, patients often experience flares. Consecutive maintenance treatment after successful induction therapy is promoted by guidelines; however, little is known about the efficacy/safety of different maintenance regimens. A systematic review on acne maintenance treatments was conducted.
BiopharmX Corp. recently announced in a press release that it has completed enrollment in a phase 2a study of BPX-01, a novel topical minocycline gel to treat acne. “This research is important in the dermatology community, which has been searching for an effective alternative to current oral antibiotic acne treatments,” AnnMarie Daniels, executive vice president of clinical and regulatory affairs for BioPharmX, stated in the release.
Evidence from recently published papers provides insight to address some common questions pertaining to the safe use of certain acne medications, said Diane Thiboutot, M.D., delivering the Alan Shalita Memorial Lecture during the MauiDerm 2016 meeting. During her talk on challenges and controversies in managing acne, Dr. Thiboutot reviewed new information about use of isotretinoin in patients with a history of pseudotumor cerebri and laboratory monitoring in patients being treated with isotretinoin or spironolactone.